RxDoctor Payments Data

Ayham Mouawad, MD

Internal Medicine · Mount Dora, FLNPI 1417261611

Payments from drug & device makers

$4,103in general payments, 2019–2025

Across 50 payments — averaging $82.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$586
  • Johnson & Johnson$354
  • Abiomed$276
  • Penumbra, Inc.$242
  • Paratek Pharmaceuticals, Inc.$242
  • Boehringer Ingelheim$235
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,103100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,103 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$147,581
Medicare patients
446
Services billed
1,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$39,472
BrilintaTicagrelor20$9,607
JardianceEmpagliflozin15$8,673
EntrestoSacubitril/Valsartan11$5,980
LantusInsulin Glargine,hum.Rec.Anlog18$1,228
Pantoprazole Sodium111$752
Atorvastatin Calcium90$626
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav57$480
ClopidogrelClopidogrel Bisulfate73$475
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen61$454
Potassium Chloride17$412
Metoprolol Succinate56$345
Hydralazine Hcl28$307
Nifedipine ErNifedipine29$303
Amiodarone Hcl16$291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$134$39,47272 claims
Boehringer IngelheimJardiance$235$8,67315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Mount Dora

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →